Ischaemic stroke in a patient with non-valvular atrial fibrillation (NVAF) despite non-vitamin K oral anticoagulant (NOAC) therapy

被引:0
|
作者
Zhen, Simon [1 ]
Chu, Fion [1 ]
Kodesh, Afek [2 ]
Kim, Jisoon [2 ]
机构
[1] Albert Einstein Coll Med, Med, Bronx, NY 10461 USA
[2] Montefiore Med Ctr, Internal Med, Bronx, NY USA
关键词
Stroke; Arrhythmias; Haematology (incl blood transfusion); Neurology; Cardiovascular medicine; VALVULAR HEART-DISEASE; RANDOMIZED EVALUATION; APPENDAGE CLOSURE; ASIAN PATIENTS; HIGHER-RISK; WARFARIN; APIXABAN; PREVENTION; GUIDELINES; DABIGATRAN;
D O I
10.1136/bcr-2023-258761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary stroke prevention in non-valvular atrial fibrillation (NVAF) is primarily with non-vitamin K oral anticoagulant (NOAC) therapy. However, 20-36% of ischaemic strokes seem to occur in patients with atrial fibrillation while already on anticoagulation. We present a case of an ischaemic stroke in an elderly female in her 70s with medical history significant for hypertension and NVAF. She had a CHA2DS2-VASc score of 3 and was on apixaban for thromboprophylaxis. She presented with neurological deficits consistent with a left middle cerebral artery stroke, confirmed via head imaging; the most likely stroke aetiology was determined to be cardioembolic in the setting of NVAF. She was treated with continuation of her apixaban at the same dosage. She displayed improved function, although with residual expressive aphasia at her 2-month neurology follow-up. Cardioembolic ischaemic stroke in NVAF despite current NOAC therapy does not have current management guidelines.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Non-vitamin K antagonist oral anticoagulant discontinuation in non-valvular atrial fibrillation patients (ASPECT-NOAC)
    Asilturk, E.
    Tulmac, M.
    Badak, O.
    Onal, T.
    Aras, D.
    Aciksari, G.
    Alper, A. T.
    Celik, A.
    Katicibasi, T.
    Ozdogan, O.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 576 - 576
  • [2] Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy
    Lin, Shin-Yi
    Tang, Sung-Chun
    Tsai, Li-Kai
    Yeh, Shin-Joe
    Huang, Chih-Fen
    Jeng, Jiann-Shing
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (12) : 1799 - 1806
  • [3] Characteristics of patients initiating oral anticoagulant therapy for management of non-valvular atrial fibrillation (NVAF)
    Masseria, C.
    Lin, I.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Unniachan, S.
    Petkun, W.
    Abdulsattar, Y.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [4] Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group
    Rebabonye B. Pharithi
    Deepti Ranganathan
    Jim O’Brien
    Emmanuel E. Egom
    Cathie Burke
    Daniel Ryan
    Christine McAuliffe
    Marguerite Vaughan
    Tara Coughlan
    Edwina Morrissey
    John McHugh
    David Moore
    Ronan Collins
    [J]. Irish Journal of Medical Science (1971 -), 2019, 188 : 101 - 108
  • [5] Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group
    Pharithi, Rebabonye B.
    Ranganathan, Deepti
    O'Brien, Jim
    Egom, Emmanuel E.
    Burke, Cathie
    Ryan, Daniel
    McAuliffe, Christine
    Vaughan, Marguerite
    Coughlan, Tara
    Morrissey, Edwina
    McHugh, John
    Moore, David
    Collins, Ronan
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 (01) : 101 - 108
  • [6] Non-valvular atrial fibrillation (NVAF)
    Roderick, E
    Cox, J
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 1997, 47 (423): : 660 - 661
  • [7] REAL-WORLD EFFECTIVENESS AND SAFETY OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOAC) IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF): A RETROSPECTIVE COHORT STUDY IN SINGAPORE
    Foo, W.
    Hui, T.
    Ong, S. K. B.
    Ng, K. H.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S303 - S303
  • [8] Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice
    Li, Yan-Guang
    Pastori, Daniele
    Lip, Gregory Y. H.
    [J]. ANNALS OF MEDICINE, 2018, 50 (04) : 288 - 302
  • [9] Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists
    Sorensen, Rikke
    Nielsen, Berit Jamie
    Pallisgaard, Jannik Langtved
    Ji-Young Lee, Christina
    Torp-Pedersen, Christian
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2017, 3 (03) : 151 - 156
  • [10] Patient with non-valvular atrial fibrillation on ineffective anticoagulant therapy
    Kot, Anna
    Starzyk, Katarzyna
    Dobaj, Lukasz
    Bakowski, Dawid
    Wozakowska-Kaplon, Beata
    [J]. KARDIOLOGIA POLSKA, 2016, 74 : 52 - 54